PDC*line Pharma

PDC*line Pharma is a Belgium-based clinical-stage Biotechnology company pioneering off-the-shelf cancer immunotherapies. Their proprietary Plasmacytoid Dendritic Cell (PDC*line) technology has shown promising results, with successful Phase I/II trials in lung cancer and melanoma. The company, founded in 2014, has attracted significant funding, including a €61M equity and non-dilutive capital and a €108M licensing deal with Korean pharmaceutical company, LG Chem Life Science. In December 2021, PDC*line Pharma secured a €5.70M grant investment from a consortium including Korea Investment Partners, Belgian Federal Investment, Noshaq, Sambrinvest, UTC 2019 BioVentureFund, Brain Asset Management, Hansongneotech, Alpha Holdings, and S.R.I.W. The company is now preparing for a randomized Phase II trial in lung cancer and a Phase Ib trial in colorectal cancer with neoantigens (PDC*neo).